Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal neostigmine dose for reversing cisatracurium-induced mild neuromuscular block in elderly patients
ChiCTR2100054685Phase 4Not yet recruiting
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of neostigmine in Postoperative residual curarization (PORC) (4 arms), sponsored by Third Xiangya Hospital, Central South University. Primary endpoint: Incidence of nausea and vomiting 1-3 days after surgery in each group. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
neostigmine
03
Conditions
Postoperative residual curarization (PORC)
Beyond the preview
Go deeper on ChiCTR2100054685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054685.